Srivastava A, Vinod P
Metabolites. 2023; 13(3).
PMID: 36984849
PMC: 10054278.
DOI: 10.3390/metabo13030409.
Zhou W, Yu X, Zhang Z, Wang X, Nie C, Zhang G
Comput Math Methods Med. 2022; 2022:1718143.
PMID: 36404910
PMC: 9671734.
DOI: 10.1155/2022/1718143.
Wang Y, Sheetz M
Front Cell Dev Biol. 2022; 10:903994.
PMID: 35646908
PMC: 9136457.
DOI: 10.3389/fcell.2022.903994.
Martinez-Perez C, Kay C, Meehan J, Gray M, Dixon J, Turnbull A
J Pers Med. 2021; 11(11).
PMID: 34834425
PMC: 8624266.
DOI: 10.3390/jpm11111073.
du Plessis M, Fourie C, Riedemann J, de Villiers W, Engelbrecht A
Cytokine Growth Factor Rev. 2021; 63:78-89.
PMID: 34794863
PMC: 8536488.
DOI: 10.1016/j.cytogfr.2021.10.005.
Ribosomal L1 domain-containing protein 1 coordinates with HDM2 to negatively regulate p53 in human colorectal Cancer cells.
Ding L, Zhang Z, Zhao C, Chen L, Chen Z, Zhang J
J Exp Clin Cancer Res. 2021; 40(1):245.
PMID: 34362424
PMC: 8344204.
DOI: 10.1186/s13046-021-02057-8.
MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.
Miles X, Vandevoorde C, Hunter A, Bolcaen J
Front Oncol. 2021; 11:703442.
PMID: 34307171
PMC: 8296304.
DOI: 10.3389/fonc.2021.703442.
PTEN and α-SMA Expression and Diagnostic Role in Oral Submucous Fibrosis and Oral Squamous Cell Carcinoma with Concomitant Oral Submucous Fibrosis.
Monteiro R, Hallikeri K, Sudhakaran A
J Oral Maxillofac Res. 2021; 12(1):e3.
PMID: 33959238
PMC: 8085678.
DOI: 10.5037/jomr.2021.12103.
Neuronal pentraxin II (NPTX2) hypermethylation promotes cell proliferation but inhibits cell cycle arrest and apoptosis in gastric cancer cells by suppressing the p53 signaling pathway.
Xu G, Fan L, Zhao S, Ouyang C
Bioengineered. 2021; 12(1):1311-1323.
PMID: 33896384
PMC: 8806217.
DOI: 10.1080/21655979.2021.1915658.
Prostate apoptosis response-4 and tumor suppression: it's not just about apoptosis anymore.
Cheratta A, Thayyullathil F, Pallichankandy S, Subburayan K, Alakkal A, Galadari S
Cell Death Dis. 2021; 12(1):47.
PMID: 33414404
PMC: 7790818.
DOI: 10.1038/s41419-020-03292-1.
Tumor Suppressors Having Oncogenic Functions: The Double Agents.
Datta N, Chakraborty S, Basu M, Ghosh M
Cells. 2021; 10(1).
PMID: 33396222
PMC: 7824251.
DOI: 10.3390/cells10010046.
Colorectal cancer (CRC) as a multifactorial disease and its causal correlations with multiple signaling pathways.
Wan M, Wang Y, Zeng Z, Deng B, Zhu B, Cao T
Biosci Rep. 2020; 40(3).
PMID: 32149326
PMC: 7087324.
DOI: 10.1042/BSR20200265.
The nuclear phosphoinositide response to stress.
Chen M, Wen T, Horn H, Chandrahas V, Thapa N, Choi S
Cell Cycle. 2020; 19(3):268-289.
PMID: 31902273
PMC: 7028212.
DOI: 10.1080/15384101.2019.1711316.
PTEN in Hereditary and Sporadic Cancer.
Ngeow J, Eng C
Cold Spring Harb Perspect Med. 2019; 10(4).
PMID: 31570378
PMC: 7117954.
DOI: 10.1101/cshperspect.a036087.
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Heavican T, Bouska A, Yu J, Lone W, Amador C, Gong Q
Blood. 2019; 133(15):1664-1676.
PMID: 30782609
PMC: 6460420.
DOI: 10.1182/blood-2018-09-872549.
Glypican-1 Promotes Tumorigenesis by Regulating the PTEN/Akt/β-Catenin Signaling Pathway in Esophageal Squamous Cell Carcinoma.
Li J, Chen Y, Zhan C, Zhu J, Weng S, Dong L
Dig Dis Sci. 2019; 64(6):1493-1502.
PMID: 30730015
DOI: 10.1007/s10620-019-5461-9.
Prothymosin-α enhances phosphatase and tensin homolog expression and binds with tripartite motif-containing protein 21 to regulate Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2 signaling in human bladder cancer.
Tsai Y, Jou Y, Tsai H, Shiau A, Wu C, Tzai T
Cancer Sci. 2019; 110(4):1208-1219.
PMID: 30719818
PMC: 6447842.
DOI: 10.1111/cas.13963.
Tumor suppression by the EGR1, DMP1, ARF, p53, and PTEN Network.
Inoue K, Fry E
Cancer Invest. 2018; 36(9-10):520-536.
PMID: 30396285
PMC: 6500763.
DOI: 10.1080/07357907.2018.1533965.
MicroRNA-203 Inhibits Long Noncoding RNA HOTAIR and Regulates Tumorigenesis through Epithelial-to-mesenchymal Transition Pathway in Renal Cell Carcinoma.
Dasgupta P, Kulkarni P, Majid S, Shahryari V, Hashimoto Y, Bhat N
Mol Cancer Ther. 2018; 17(5):1061-1069.
PMID: 29440295
PMC: 5932222.
DOI: 10.1158/1535-7163.MCT-17-0925.
MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas.
Laroche A, Chaire V, Algeo M, Karanian M, Fourneaux B, Italiano A
Oncotarget. 2017; 8(33):53968-53977.
PMID: 28903316
PMC: 5589555.
DOI: 10.18632/oncotarget.16345.
